Evaluating surgical options for lung cancer patients after initial treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the feasibility, safety, and prognosis of converting from pneumonectomy to lobectomy in patients with operable non-small cell lung cancer (NSCLC) who have undergone neoadjuvant or induction therapy. The study will involve a multicenter approach with an anticipated sample size of 50 patients over a duration of five years. Participants will undergo a series of preoperative evaluations and treatments, including neoadjuvant immuno-chemotherapy, followed by surgical intervention. Outcomes such as perioperative complications, survival rates, and quality of life will be meticulously recorded and analyzed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patients voluntarily participate in the study, have good compliance, can cooperate with the requirements of the experiment to complete the observation and follow-up, and sign the informed consent form.
* Aged over 18 years old, under 75 years old; male and female are not limited;
* Pathologically confirmed non-small cell lung cancer with clinical stage T2-4N0-2, resectable non-small cell lung cancer, potentially needing pneumonectomy and receiving neoadjuvant or induction therapy.
* ASA score: Grade I-III;
* The cardiopulmonary function evaluation can meet the requirements for radical lung cancer surgery, and the liver and kidney functions are normal.

Exclusion Criteria:

* Those with serious cardiac, pulmonary, hepatic, and renal dysfunctions, unable to tolerate the surgery;
* Those with uncontrollable neurological or psychiatric diseases or mental disorders, poor compliance, and being unable to cooperate and describe the treatment response.
* Those who are going to undergo emergency surgery or palliative surgery due to lung abscess or hemoptysis.
* Those who have been treated, or are undergoing neoadjuvant or induction radiotherapy or targeted therapy.
* Those who have a combined history of other malignant tumors
* Those who have a history of thoracic surgery
* Those who are pregnant or breastfeeding women
* Patients of childbearing age who refuse to use contraception.

Where it's running

• Ruijin hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Hecheng Li
• Email: lihecheng2000@hotmail.com
• Phone: 13917113402

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.